|
New! 2008 UPDATE: The first research paper funded by this research is now
appearing in the British Journal of Haemotology. Scroll down for title and abstract.
Our daughter, Teresa Michelle Bogstad, passed away on February
18, 2005 after a life-long battle with Langerhans Cell
Histiocytosis, also called LCH. She is survived by her
(non-identical) twin sisters. While LCH is not technically classed
as a cancer, currently, it is treated by pediatric cancer doctors
with chemotherapy drugs. A memorial service was held on Friday,
February 25th at
Goddard Chapel at Tufts
University.
Terry's story
In Teresa's memory, we are trying to raise money to fund a
very targeted research study into a promising new drug
against LCH. LCH is an "orphan" disease, meaning that the
number of children who will get LCH in this country is too
small for LCH research to typically qualify for federal
funds. Even Boston Children's Hospital, a major children's
hospital in a big city, sees only 2-3 children diagnosed with LCH
each year. But: It looks like we could be less than 3
years away from going into human clinical trials with a
cure for this disease that spares affected children the
horrible side-effects, risks, and complications of general
chemotherapy. Such a drug will not save thousands; but if
we save even a few children like Teresa each year,
it will be worth developing.
About LCH and the approach to a cure
Contributions should be sent to The Children's Cancer Foundation --
The Teresa Bogstad Fund". The Children's Cancer Foundation is a
501(c)(3) charitable organization, and all contributions are tax
deductible. I have spoken to the founder, Shirley Howard, and every
dollar raised for the Teresa Bogstad fund will go 100% to
Dr. Bob
Arceci's research group at Johns Hopkins to pursue promising new
therapy for LCH. Here's Why we chose the Children's Cancer foundation for this fundraiser.
How to contribute:
Make your check out to "The Children's Cancer Foundation".
Somewhere on your check, mark it "For the Teresa Bogstad fund".
Send your check to: The Children's Cancer Foundation, 1052 Flagtree Lane,
Baltimore, MD 21208.
If you prefer, you can give your checks directly to us, but if so,
please make sure they are made out to "The Children's Cancer Foundation"
not to us personally!
If 5,000 people give $20 each, 1000 people give $100 each, 50 people give $1000 each, and 5 people give $10,000 each,
we will have raised $300,000. This is
enough money for the 3-years of laboratory work and
research in mice that are a necessary precursor to human clinical trials
(at which point the project could qualify for funds from
the FDA's orphan disease division to start human clinical trials.)
If instead you wish to run any sort of fundraiser in
your community to help raise money
(a benefit concert; a golf tournament) let us
know and we'd love to help you with it.
New! 2008 UPDATE: The first research paper funded by this research is now
appearing in the British Journal of Haemotology. Here is the information:
Br J Haematol. 2008 Feb;140(4):420-8. Epub 2007 Dec 19.
Title: Telomere length shortening in Langerhans cell histiocytosis.
Authors: Bechan GI, Meeker AK, De Marzo AM, Racke F, Jaffe R, Sugar E, Arceci RJ.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Langerhans cell histiocytosis (LCH) is a clonal, proliferative
disorder of phenotypically immature CD1a(+) Langerhans cells
(LC). The aetiology of LCH is unknown and data supporting an
immune dysregulatory disorder as well as a clonal neoplasm have
been reported. Telomere shortening has been associated with
cancers and premalignant lesions as well as promoting chromosomal
instability. To determine whether LCH LC have altered telomere
lengths, we used dual detection of CD1a expression by
immunofluorescence and telomere length by fluorescence in situ
hybridization of LCH LC and lymphocytes in local, multisystem and
systemic LCH and compared these with telomere lengths of LC and
lymphocytes in reactive lymph nodes. LCH LC showed significantly
shorter telomere lengths than LC from reactive lymph nodes or
unaffected skin. Lymphocyte telomere lengths showed similar
profiles among the different samples. These data show a
significant telomere shortening in LCH LC in all stages of disease
involvement compared with LC from reactive lymph nodes, suggesting
that LCH may share mechanisms of telomere shortening and survival
with clonal preneoplastic disorders and cancer, although an
initiating infectious or immune event is still possible.
Here's a dense hard to read page that I
wrote about what I have learned both about LCH and about issues with
treating it given our current diagnostic abilities and current drugs
we have available. It includes a description of the LCH skin rash that
I hope is helpful for those that are not sure what it looks like. The
intended audience for this page is parents of LCH patients and their
doctors.
The reason for all this is the kids who are still battling this horrid
disease.
Here's a link to a story about another great kid battling LCH in California. Send your hopes and prayers for 2-year old Patrick.
Here's a link to Ivy's website -- Ivy is a baby in California also battling LCH.
New! Here's a link to a page for a brave 2 year old named Logan who was just diagnosed with LCH this past April.
Here are some more sites I found recently with kids battling LCH:
Christopher's story, Aidan's webpage. , Ellie Clare,
Christian's LCH . Please pray for them all.
|